XML 24 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)
280 Months Ended 0 Months Ended 6 Months Ended 0 Months Ended 0 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2013
Dec. 31, 2012
Jun. 30, 2014
Senior convertible notes due December 31, 2019
Deerfield
Jun. 30, 2014
Senior convertible notes due December 31, 2019
Deerfield
Facility Agreement
Maximum
Jul. 01, 2013
Senior convertible notes due December 31, 2019
Deerfield
Notes Issued in Four Equal Tranches
Tranche
Jun. 30, 2014
Senior convertible notes due December 31, 2019
Deerfield
Notes Issued in Four Equal Tranches
Jul. 01, 2013
Senior convertible notes due December 31, 2019
Deerfield
Notes Issued in Four Equal Tranches
Jun. 30, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
May 06, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
Feb. 28, 2014
Senior convertible notes due December 31, 2019
Deerfield
Tranche B notes
Aug. 11, 2014
Subsequent Event
License and Collaboration Agreement with Sanofi
Aug. 11, 2014
Subsequent Event
License and Collaboration Agreement with Sanofi
Aug. 11, 2014
Subsequent Event
License and Collaboration Agreement with Sanofi
Second Amendment Facility Agreement
Aug. 11, 2014
Subsequent Event
License and Collaboration Agreement with Sanofi
Sanofi-Aventis Deutschland GmbH
Jul. 18, 2014
Subsequent Event
Senior convertible notes due December 31, 2019
Deerfield
Fourth tranche
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                                  
Deficit accumulated during the development stage $ 2,421,824,000 $ 2,296,402,000                              
Goodwill impairment 151,428,000                                
Cash flow from operation since inception (1,800,000,000)                                
Cash and cash equivalents 41,214,000 70,790,000 28,529,000 61,840,000                          
Available borrowings under loan agreement 30,100,000                                
Accrued interest on loan arrangement 2,000,000                                
Debt facility principal amount               120,000,000 160,000,000     90,000,000          
Number of equal tranches             4                    
Debt facility periodic principal amount                 40,000,000                
Debt facility carrying amount         40,000,000                        
Principal amount of notes purchased                     20,000,000           40,000,000
Maximum available amount of credit facility under covenant restrictions           25,000,000                      
Additional sales of notes 119,500,000                 70,000,000              
Upfront fee                         150,000,000        
Potential milestone payment                           775,000,000      
Profits and losses sharing percentage                         35.00%     65.00%  
Maximum secured loan facility                 $ 160,000,000           $ 175,000,000